The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Chemotherapy for pancreatic cancer
Abstract
Chemotherapy is an important part of multimodality pancreatic cancer treatment. After curative resection, adjuvant chemotherapy can significantly improve disease free survival and overall survival. The current standard of care is six months adjuvant chemotherapy with modified folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (mFOLFIRINOX) in patients fit enough for this protocol, otherwise six months of gemcitabine and capecitabine based on the European Study Group for Pancreatic Cancer (ESPAC)-4 study. In patients with metastatic disease, combination chemotherapy according to the FOLFIRINOX protocol or with gemcitabine plus nab-paclitaxel is an important improvement to gemcitabine monotherapy that was the standard for many years. Patients not fit for combination chemotherapy however may still benefit from gemcitabine. Patients with good performance status may benefit from second-line chemotherapy. Chemoradiation has long been used in locally advanced pancreatic cancer but is now tempered following the LAP07 study. This trial showed no difference in overall survival in those patients with stable disease after four months of gemcitabine (with or without erlotinib) randomized to either continuation of gemcitabine therapy or chemoradiation (54Gy with capecitabine). As an alternative to radiation, other forms local therapies including radiofrequency ablation, irreversible electroporation, high-intensity focused ultrasound, microwave ablation and local anti-KRAS therapy (using siG12D-LODER) are currently under investigation. Given the systemic nature of pancreas cancer from an early stage, the success of any local approach other than complete surgical resection (with adjuvant systemic therapy) is likely to be very limited. In patients with locally advanced, irresectable cancer, chemotherapy may offer the chance for secondary resection with a survival similar to patients with primary resectable disease. Downstaging regimens need to be evaluated in prospective randomized trials in order to make firm recommendations. Selection of patient groups for specific therapy including cytotoxics is becoming a reality using assays based on drug cellular transport and metabolism, and molecular signatures. Going forward, high throughput screening of different chemotherapy agents using molecular signatures based on patients' derived organoids holds considerable promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationOettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Self-citationSubtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Pancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection
Kaiser, M. H. (1985) · Archives of Surgery · doi:10.1001/archsurg.1985.01390320023003 · Cited by 1,406
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Self-citationCancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J. L., Conroy, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv295 · Cited by 1,300
Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222
Self-citationIdentification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Self-citationUesaka, K., Boku, N., Fukutomi, A., Okamura, Y., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30583-9 · Cited by 1,115
Neoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06651-x · Cited by 1,111
Self-citationOrganoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
Hammel, P., Huguet, F., van Laethem, J.-L., Goldstein, D., Glimelius, B., Artru, P., Borbath, I., Bouché, O., Shannon, J., André, T., et al. (2016) · JAMA · doi:10.1001/jama.2016.4324 · Cited by 1,092
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S. W., Benson, A. B., Binder, E., Cardin, D. B., Cha, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0131 · Cited by 1,020
Suker, M., Beumer, B. R., Sadot, E., Marthey, L., Faris, J. E., Mellon, E. A., El-Rayes, B. F., Wang-Gillam, A., Lacy, J., Hosein, P. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00172-8 · Cited by 939
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 823
Self-citationJang, J.-Y., Han, Y., Lee, H., Kim, S.-W., Kwon, W., Lee, K.-H., Oh, D.-Y., Chie, E. K., Lee, J. M., Heo, J. S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002705 · Cited by 681
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618
Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., Strobel, O., Jäger, D., Ulrich, A., & Büchler, M. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001850 · Cited by 529
Self-citationVersteijne, E., Vogel, J. A., Besselink, M. G., Busch, O. R. C., Wilmink, J. W., Daams, J. G., van Eijck, C. H. J., Groot Koerkamp, B., Rasch, C. R. N., & van Tienhoven, G. (2018) · British Journal of Surgery · doi:10.1002/bjs.10870 · Cited by 519
Hingorani, S. R., Zheng, L., Bullock, A. J., Seery, T. E., Harris, W. P., Sigal, D. S., Braiteh, F., Ritch, P. S., Zalupski, M. M., Bahary, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9564 · Cited by 510
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Oettle, H., Riess, H., Stieler, J. M., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 487
Quaresma, M., Coleman, M. P., & Rachet, B. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61396-9 · Cited by 461
Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7657 · Cited by 455
Self-citationMeta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Self-citationHeinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Mueller, S., Engleitner, T., Maresch, R., Zukowska, M., Lange, S., Kaltenbacher, T., Konukiewitz, B., Öllinger, R., Zwiebel, M., Strong, A., et al. (2018) · Nature · doi:10.1038/nature25459 · Cited by 431
Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Létourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 403
Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection
Gemenetzis, G., Groot, V. P., Blair, A. B., Laheru, D. A., Zheng, L., Narang, A. K., Fishman, E. K., Hruban, R. H., Yu, J., Burkhart, R. A., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002753 · Cited by 401
Mokdad, A. A., Minter, R. M., Zhu, H., Augustine, M. M., Porembka, M. R., Wang, S. C., Yopp, A. C., Mansour, J. C., Choti, M. A., & Polanco, P. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5081 · Cited by 400
Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70236-0 · Cited by 378
Self-citationEvaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Hu, Z. I., Shia, J., Stadler, Z. K., Varghese, A. M., Capanu, M., Salo-Mullen, E., Lowery, M. A., Diaz, L. A., Mandelker, D., Yu, K. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3099 · Cited by 372
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 370
Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., Maitra, A., Mohile, S. G., Mumber, M., Schulick, R., Shapiro, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5553 · Cited by 366
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 337
Self-citationMetastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O’Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1412 · Cited by 332
Sinn, M., Bahra, M., Liersch, T., Gellert, K., Messmann, H., Bechstein, W., Waldschmidt, D., Jacobasch, L., Wilhelm, M., Rau, B. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6463 · Cited by 293
Gill, S., Ko, Y.-J., Cripps, C., Beaudoin, A., Dhesy-Thind, S., Zulfiqar, M., Zalewski, P., Do, T., Cano, P., Lam, W. Y. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5776 · Cited by 288
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
Lomberk, G., Blum, Y., Nicolle, R., Nair, A., Gaonkar, K. S., Marisa, L., Mathison, A., Sun, Z., Yan, H., Elarouci, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04383-6 · Cited by 261
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Heining, C., Horak, P., Uhrig, S., Codo, P. L., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 240
Self-citationGonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 225
Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., Vogel, V., Klaus, B., Nadler, W., Rösli, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4038 · Cited by 224
Self-citationLowery, M. A., Jordan, E. J., Basturk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B., Askan, G., Maynard, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0899 · Cited by 212
Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
Drilon, A., Somwar, R., Mangatt, B. P., Edgren, H., Desmeules, P., Ruusulehto, A., Smith, R. S., Delasos, L., Vojnic, M., Plodkowski, A. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1004 · Cited by 202
Kalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice
Seifert, L., Werba, G., Tiwari, S., Giao Ly, N. N., Nguy, S., Alothman, S., Alqunaibit, D., Avanzi, A., Daley, D., Barilla, R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.070 · Cited by 190
Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches
Tuveson, D. A., & Neoptolemos, J. P. (2012) · Cell · doi:10.1016/j.cell.2011.12.021 · Cited by 188
Self-citationRougier, P., Riess, H., Manges, R., Karasek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 184
Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma
Ajani, J. A., Faust, J., Ikeda, K., Yao, J. C., Anbe, H., Carr, K. L., Houghton, M., & Urrea, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.917 · Cited by 182
Portal, A., Pernot, S., Tougeron, D., Arbaud, C., Bidault, A. T., de la Fouchardière, C., Hammel, P., Lecomte, T., Dréanic, J., Coriat, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.328 · Cited by 182
Hou, S., Tiriac, H., Sridharan, B. P., Scampavia, L., Madoux, F., Seldin, J., Souza, G. R., Watson, D., Tuveson, D., & Spicer, T. P. (2018) · SLAS Discovery · doi:10.1177/2472555218766842 · Cited by 169
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 165
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K., Bailey, P., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 162
Van Tienhoven, G., Versteijne, E., Suker, M., Groothuis, K. B. C., Busch, O. R., Bonsing, B. A., de Hingh, I. H. J. T., Festen, S., Patijn, G. A., de Vos-Geelen, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba4002 · Cited by 161
Wagner, M., Antunes, C., Pietrasz, D., Cassinotto, C., Zappa, M., Cunha, A. S., Lucidarme, O., & Bachet, J. (2016) · European Radiology · doi:10.1007/s00330-016-4632-8 · Cited by 150
Rombouts, S. J. E., Walma, M. S., Vogel, J. A., van Rijssen, L. B., Wilmink, J. W., Mohammad, N. H., van Santvoort, H. C., Molenaar, I. Q., & Besselink, M. G. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5373-2 · Cited by 147
Hidalgo, M. M., Plaza, C., Musteanu, M., Illei, P. B., Brachmann, C. B., Heise, C. C., Pierce, D. W., Lopez-Casas, P. P., Menéndez, C., Tabernero, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3222 · Cited by 141
Conroy, T., Hammel, P. R., Hebbar, M., Abdelghani, M. B., Wei, A. C.-C., Raoul, J., Choné, L., François, É., Artru, P., Biagi, J. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba4001 · Cited by 140
Heinemann, V., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302759 · Cited by 124
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Şahin, İ. H., Askan, G., Hu, Z., & O'Reilly, E. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx503 · Cited by 115
Systemic treatment of advanced pancreatic cancer
Heinemann, V., Haas, M., & Boeck, S. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.004 · Cited by 114
Dhir, M., Zenati, M. S., Hamad, A. B., Singhi, A. D., Bahary, N., Hogg, M. E., Zeh, H. J., & Zureikat, A. H. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6512-8 · Cited by 110
Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Lupinacci, R. M., Goloudina, A. R., Buhard, O., Bachet, J., Maréchal, R., Demetter, P., Cros, J. F., Bardier–Dupas, A., Collura, A., Cervera, P., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.11.009 · Cited by 109
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604436 · Cited by 104
Self-citationEvans, D. B., George, B., & Tsai, S. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4649-2 · Cited by 95
Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 95
Self-citationNeoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Habermehl, D., Kessel, K. A., Welzel, T., Hof, H., Abdollahi, A., Bergmann, F., Rieken, S., Weitz, J., Werner, J., Schirmacher, P., et al. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-28 · Cited by 91
Self-citationLocally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies
Ruarus, A. H., Vroomen, L. G. P. H., Puijk, R. S., Scheffer, H. J., & Meijerink, M. R. (2018) · Cancers · doi:10.3390/cancers10010016 · Cited by 90
Laghi, L., Beghelli, S., Spinelli, A., Bianchi, P. P., Basso, G., Caro, G. D., Brecht, A., Celesti, G., Turri, G., Bersani, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046002 · Cited by 72
Scheithauer, W., Ramanathan, R. K., Moore, M. J., Macarulla, T. M., Goldstein, D., Hammel, P. R., Kunzmann, V., Liu, H., McGovern, D. M. T., Romano, A., et al. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.01.03 · Cited by 67
Zhang, Y., Höchster, H. S., Stein, S., & Lacy, J. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0025-y · Cited by 58
Borderline resectable pancreatic cancer
Hackert, T., Ulrich, A. B., & Büchler, M. W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.039 · Cited by 56
Self-citationGermline mutations in pancreatic cancer and potential new therapeutic options
Pihlak, R., Valle, J. W., & McNamara, M. G. (2017) · Oncotarget · doi:10.18632/oncotarget.17291 · Cited by 53
Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
Lambert, A., Gavoille, C., & Conroy, T. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17713879 · Cited by 53
Pancreatic cancer: are more chemotherapy and surgery needed?
Deplanque, G., & Demartines, N. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30126-5 · Cited by 51
Current Development of Anti-Cancer Drug S-1
Chhetri, P. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19345.8776 · Cited by 46
Haas, M., Siveke, J. T., Schenk, M., Lerch, M. M., Caca, K., Freiberg‐Richter, J., von Weikersthal, L. F., Kullmann, F., Reinacher-Schick, A. C., Fuchs, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.008 · Cited by 45
The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings
Badiyan, S. N., Molitoris, J. K., Chuong, M. D., Regine, W. F., & Kaiser, A. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.01.012 · Cited by 44
Pishvaian, M. J., Rolfo, C. D., Liu, S. V., Multani, P. S., Maneval, E. C., & Garrido‐Laguna, I. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.521 · Cited by 38
Bachet, J., Hammel, P. R., Desrame, J., Meurisse, A., Chibaudel, B., André, T., Debourdeau, P., Dauba, J., Lecomte, T., Seitz, J., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30046-8 · Cited by 36
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
for the European Study Group for Pancreatic Cancer, Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0004-2 · Cited by 35
Self-citationMosquera, C., Maglic, D., & Zervos, E. E. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.07.003 · Cited by 34
Viaud, J., Brac, C., Artru, P., Pabic, E. L., Leconte, B., Bodère, A., Pracht, M., Sourd, S. L., Edeline, J., & Lièvre, A. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.02.007 · Cited by 33
Sarabi, M., Mais, L., Oussaid, N., Desseigne, F., Guibert, P., & de la Fouchardière, C. (2017) · Oncology Letters · doi:10.3892/ol.2017.6061 · Cited by 33
nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer
Neeße, A., Michl, P., Tuveson, D. A., & Ellenrieder, V. (2014) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1366002 · Cited by 31
DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development
Golan, T., & Javle, M. M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0133 · Cited by 28
Vogel, A., Kullmann, F., Kunzmann, V., Al‐Batran, S., Oettle, H., Plentz, R. R., Siveke, J. T., Springfeld, C., & Riess, H. B. (2015) · Oncology Research and Treatment · doi:10.1159/000441310 · Cited by 26
Self-citationMiddleton, G., Greenhalf, W., Costello, E., Shaw, V. E., Cox, T. F., Ghaneh, P., Palmer, D. H., & Neoptolemos, J. P. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.468 · Cited by 24
Self-citationMonoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer
Cinar, P., & Tempero, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182758985 · Cited by 23
Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?
Chuong, M. D., Boggs, D. H., Patel, K. N., & Regine, W. F. (2014) · PubMed · doi:10.3978/j.issn.2078-6891.2014.025 · Cited by 23
Sinn, M., Liersch, T., Gellert, K., Riess, H. B., Stübs, P., Waldschmidt, D., Pelzer, U., Stieler, J., Striefler, J. K., Bahra, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.18 · Cited by 23
Zhang, H., Kellett, C., Lambert, P. J., & Kim, C. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.03.003 · Cited by 19
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 16
Cohen, S. J., O’Neil, B. H., Berlin, J. D., Ames, P., McKinley, M., Horan, J. D., Catalano, P. M., Davies, A. M., Weekes, C. D., & Leichman, L. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2981-2 · Cited by 13
for the European Study Group for Pancreatic Cancer, Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0005-1 · Cited by 13
Self-citationNeoadjuvant Chemotherapy in Pancreatic Cancer
Hank, T. P., Büchler, M. W., & Neoptolemos, J. P. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2020.6273 · Cited by 3
Self-citation
Cited by
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Self-citationPancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
Zhao, Z., & Liu, W. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962117 · Cited by 348
Liang, L., Ding, Y., Yu, Y., Liu, K., Rao, S., Ge, Y., & Zeng, M. (2021) · BMC Medical Imaging · doi:10.1186/s12880-021-00605-4 · Cited by 13
Metadata
- Authors
- Springfeld, C., Jäger, D., Büchler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P.
- Venue
- La Presse Médicale
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 48
- Issue
- 3
- Pages
- e159-e174
- ISSN
- 0032-7867 (ISSN-L)
- 0755-4982
- OpenAlex
- W2921554521
- Cited by
- 281
- References
- 118
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.